中心体蛋白55在肺腺癌组织的表达及其临床意义  

The expression and clinical significance of centrosome protein 55 in lung adenocarcinoma

作　　者：涂顺珂 冯旭[1] 蔡长伟 黄勋功 Tu Shunke;Feng Xu;Cai Changwei;Huang Xungong(Department of Cardiothoracic Surgery,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院心胸外科,南宁530021

出　　处：《中华实验外科杂志》2022年第8期1468-1471,共4页Chinese Journal of Experimental Surgery

基　　金：广西自然科学基金面上项目(2016GXNSFAA380256)。

摘　　要：目的采用生物信息学方法分析中心体蛋白55(CEP55)在肺腺癌中的表达, 探究CEP55在肺腺癌中的潜在机制及其临床意义。方法从癌症基因组图谱(TCGA)数据库下载肺腺癌转录组和临床数据, 借助R语言和Perl软件进行数据处理, 使用Wilcoxon秩和检验、Kruskal-Wallis检验及logistics回归分析CEP55表达差异性以及与临床病理参数的相关性, Kaplan-Meier和Cox回归分析肺腺癌患者预后影响因素;使用基因富集分析(GSEA)方法分析预测CEP55在肺腺癌中参与的信号通路。组间比较采用Wilcoxon秩和检验, 多组比较采用Kruskal-Wallis检验。结果 CEP55在肺腺癌组织中的表达量明显高于癌旁组织[6.151(2.671, 10.464)比0.628(0.428, 0.932), Z=-11.959, P<0.05], CEP55表达量与年龄[<65岁7.220(3.590, 11.062)比≥65岁5.320(2.194, 9.386), Z=-3.478, P<0.05]、性别[女性5.315(2.218, 9.379)比男性7.213(2.903, 11.533), Z=-3.049, P<0.05]、肿瘤分期[Ⅰ 4.969(2.163, 8.927)比Ⅱ 6.913(3.397, 11.513)比Ⅲ 7.444(4.127, 13.286)比Ⅳ 8.192(2.624, 13.623), χ^(2)=21.624, P<0.05]、T分期[T1 4.166(1.964, 7.978)比T2 6.949(3.458, 11.354)比T3 5.982(2.734, 11.482)比T4 8.542(2.118, 12.132), χ^(2)=20.711, P<0.05]及N分期[N0 5.366(2.213, 9.711)比N1+N2+N3 7.417(3.949, 12.210), Z=-3.911, P<0.05]显著相关, CEP55高表达患者比低表达患者更容易进展到晚期。Kaplan-Meier生存分析表明CEP55表达水平越高, 患者预后越差(P<0.05)。CEP55表达量[风险比(HR)=1.252, 95%可信区间(CI):1.046~1.499, P<0.05]可作为肺腺癌患者的独立预后因素。GSEA富集分析显示CEP55高表达主要与细胞周期信号通路、卵母细胞减数分裂、p53信号通路、RNA降解和DNA复制途径相关。结论 CEP55在肺腺癌组织中显著高表达, 且CEP55高表达与肺腺癌患者预后不良相关, 可作为肺腺癌患者的独立预后因素, p53信号通路调控CEP55表达在肺腺癌中发挥重要作用。Objective To analyze the expression of centrosome protein 55(CEP55)in lung adenocarcinoma by bioinformatics method,and to explore the potential mechanism and clinical significance of CEP55 in lung adenocarcinoma.Methods The transcriptome and clinical data of lung adenocarcinoma were downloaded from cancer Genome Atlas(TCGA)database and processed with R language and Perl software.Wilcoxon rank-sum test,Kruskal-Wallis test and Logistics regression were used to analyze the difference of CEP55 expression and its correlation with clinicopathological parameters.Kaplan-meier and Cox regression were used to analyze the prognostic factors of lung adenocarcinoma patients.Gene enrichment analysis(GSEA)was used to analyze and predict the signaling pathway involved in CEP55 in lung adenocarcinoma.Wilcoxon rank-sum test was used for comparison between groups,and Kruskal-Wallis test was used for comparison between groups.Results The expression of CEP55 in lung adenocarcinoma was significantly higher than that in adjacent tissues[6.151(2.671,10.464)vs.0.628(0.428,0.932),Z=-11.959,P<0.05].The expression of CEP55 was significantly correlated with age[<65 years:7.220(3.590,11.062)vs.≥65 years:5.320(2.194,9.386),Z=-3.478,P<0.05],gender[female 5.315(2.218,9.379)vs.male 7.213(2.903,11.533),Z=-3.049,P<0.05],tumor stage[Ⅰ4.969(2.163,8.927)vs.Ⅱ6.913(3.397,11.513)vs.Ⅲ7.444(4.127,13.286)vs.Ⅳ8.192(2.624,13.623),χ^(2)=21.624,P<0.05],T stage[T14.166(1.964,7.978)vs.T26.949(3.458,11.354)vs.T35.982(2.734,11.482)vs.T48.542(2.118,12.132),χ^(2)=20.711,P<0.05]and N stage[N05.366(2.213,9.711)vs.N1+N2+N37.417(3.949,12.210),Z=-3.911,P<0.05].Patients with high expression of CEP55 were more likely to progress to advanced stage.Kaplan Meier survival analysis showed that the higher the expression level of CEP55,the worse the prognosis(P<0.05).The expression of CEP55[hazard ratio:1.252;95%confidence interval:1.046-1.499,P<0.05]could be used as an independent prognostic factor in patients with lung adenocarcinoma.GSEA enrichment analysis showed t

关 键 词：中心体蛋白55 肺腺癌 基因表达 信号通路 

分 类 号：R734.2[医药卫生—肿瘤]